TB-500 10mg

About TB-500 10mg

TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (TB4), a naturally occurring 43-amino acid protein found in virtually all mammalian cell types. While full-length Thymosin Beta-4 serves as the primary intracellular G-actin sequestering protein — regulating actin polymerisation, cell motility, and cytoskeletal dynamics — TB-500 isolates the key functional domain responsible for many of these biological activities. This makes it a practical and widely used research tool for studying actin-dependent processes including cell migration, wound repair, and tissue remodelling.

The distinction between TB-500 and full-length Thymosin Beta-4 is worth noting for research purposes. TB-500 encompasses the central actin-binding domain of TB4, retaining the capacity to promote cell migration and modulate inflammatory responses, but it is not identical to the parent protein in structure or in the full scope of its biological interactions. Researchers working with TB-500 are studying a defined fragment with well-characterised activity at the actin-regulation level, making it a focused tool for investigating specific aspects of TB4 biology without the complexity of the complete molecule.

Research Summary

The role of Thymosin Beta-4 in cardiac repair was brought to wide attention by the landmark study from Bock-Marquette et al., published in Nature in 2004. This research demonstrated that TB4 promoted survival of cardiomyocytes following ischaemic injury in mouse models, with evidence of reduced scar formation and improved cardiac function. The study identified TB4’s capacity to activate the pro-survival kinase Akt and to promote angiogenesis in damaged cardiac tissue. This work established TB4 — and by extension its active fragment TB-500 — as a molecule of significant interest in cardiovascular repair research, and it remains one of the most cited studies in the thymosin peptide literature.

Wound healing has been one of the most extensively studied applications of TB-500 and its parent protein. In dermal wound models, TB4 and TB-500 have been shown to accelerate wound closure through multiple mechanisms: enhanced keratinocyte and endothelial cell migration, increased collagen deposition, and promotion of angiogenesis at the wound site. The actin-regulatory function of the peptide is central to these effects, as cell migration during wound repair depends fundamentally on dynamic cytoskeletal remodelling. Research groups have documented faster wound closure rates and improved tissue quality in treated animal models compared to controls.

The corneal healing research led by Sosne et al. has provided some of the most detailed mechanistic data on TB4’s tissue repair properties. Across a series of studies, the Sosne group demonstrated that TB4 promoted corneal epithelial cell migration, reduced inflammation, and accelerated healing in models of corneal injury including alkali burns and surgical wounds. These studies highlighted the peptide’s anti-inflammatory properties alongside its pro-migratory effects, suggesting a dual mechanism in which TB4 both drives tissue repair and dampens the inflammatory cascade that can impede healing. This body of work has positioned the thymosin beta-4 pathway as a significant area of ophthalmic research.

Angiogenesis — the formation of new blood vessels — is another well-documented effect of TB4 and TB-500 in research models. Studies have shown that the peptide promotes endothelial cell differentiation and tubule formation in vitro, and supports new vessel growth in vivo. This angiogenic capacity is thought to contribute to the compound’s observed effects in both cardiac repair and wound healing, where adequate blood supply to damaged tissue is a critical determinant of recovery. The interplay between actin regulation, cell migration, and vascular development represents a mechanistically rich area of ongoing investigation.

The anti-inflammatory properties of TB-500 have been characterised across several model systems. Research has demonstrated downregulation of pro-inflammatory cytokines and chemokines in treated tissues, alongside modulation of inflammatory cell infiltration at injury sites. These effects appear to operate independently of — but synergistically with — the peptide’s cell migration and angiogenic activities. In models of joint inflammation and muscular injury, TB-500 treatment has been associated with reduced inflammatory markers and improved functional recovery, suggesting broad relevance across inflammatory tissue repair contexts.

Hair follicle biology represents a more recent but growing area of TB-500 research. Studies have shown that Thymosin Beta-4 is expressed in hair follicle stem cells and plays a role in hair follicle cycling and growth. In animal models, administration of TB4 has been associated with accelerated hair growth and increased follicle activity, with proposed mechanisms involving stimulation of follicular stem cell migration and differentiation. While this research is still in relatively early stages compared to the wound healing and cardiac repair literature, it has generated interest among researchers studying regenerative biology and the role of actin-regulatory peptides in stem cell-driven tissue renewal.